BioNTech looks to the future as WHO declares COVID-19 emergency over

9 May 2023

The World Health Organization’s (WHO) declaration on Friday that the COVID-19 global emergency status has ended, and that the virus should now be managed alongside other infectious diseases, formally brings to an end what has been an uncertain and difficult time for much of the world.

But for BioNTech (Nasdaq: BNTX), a German company with no previous on-market products that suddenly found itself bringing in billions from sales of Comirnaty, a vaccine for COVID-19 sold in partnership with Pfizer (NYSE: PFE), the announcement, which means that the virus should now be managed along with other infectious diseases, underlined the need to seek growth opportunities elsewhere.

"For the remainder of 2023, we are focused on advancing our disruptive platforms against solid tumors and accelerating clinical programs in infectious diseases of high global need"This fact was likely already obvious on looking at BioNTech’s first-quarter financial results, which were presented on Monday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK